Table 1.
Characteristics of Study Participants (N = 39)
| Characteristic | Cases (N = 10) | Controls (N = 29) | Combined (N = 39) |
|---|---|---|---|
| Age at HCT, yr, median (range) | 62.6 (42.1–74.6) | 64.6 (38.5–74.7) | 64.6 (38.5–74.7) |
| Male sex, n (%) | 8 (80.0) | 23 (79.3) | 31 (79.5) |
| Race/ethnicity, n (%) | |||
| Non-Hispanic white | 7 (70.0) | 27 (69.0) | 27 (69.2) |
| Hispanic | 0 | 3 (10.3) | 3 (7.7) |
| Other | 3 (30.0) | 9 (20.7) | 9 (23.1) |
| Diagnosis, n (%) | |||
| Non-Hodgkin lymphoma | 6 (60.0) | 18 (62.1) | 24 (61.5) |
| Hodgkin lymphoma | 2 (20.0) | 5 (17.2) | 7 (18.0) |
| Multiple myeloma | 2 (20.0) | 6 (20.7) | 8 (20.5) |
| Conditioning regimen, n (%) | |||
| BEAM | 4 (40.0) | 13 (44.8) | 17 (43.5) |
| Zevalin + BEAM | 2 (20.0) | 5 (17.2) | 7 (18.0) |
| BCNUCYVP16 | 2 (20.0) | 5 (17.2) | 7 (18.0) |
| Melphalan | 2 (20.0) | 6 (20.7) | 8 (20.5) |
| Causes of death, N (%) | |||
| Subsequent hematologic neoplasm | 4 (40.0) | – | – |
| Subsequent solid neoplasm | 2 (20.0) | – | – |
| Multi-organ failure | 2 (20.0) | – | – |
| Cardiovascular disease | 1 (10.0) | – | – |
| Respiratory failure | 1 (10.0) | – | – |
BEAM indicates carmustine, etoposide, cytarabine, and melphalan; BCNUCYVP16, carmustine, cyclophosphamide, and etoposide.